Johnson & Johnson announced that the Phase 3 MonumenTAL-3 study demonstrated that TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, significantly improved progression-free survival (up to 81.3%) and overall survival (up to 89.2%) at 24 months in patients with relapsed or refractory multiple myeloma. The study showed a 72% reduction in disease progression or death risk compared to standard treatment. These results mark the first Phase 3 evidence of a GPRC5D bispecific antibody combination's effectiveness earlier in treatment, potentially expanding therapeutic options. Johnson & Johnson is pursuing regulatory approvals to bring this combination to patients globally.
Three dividend stocks—Johnson & Johnson, Realty Income, and JPMorgan Chase—are highlighted as strong retirement investments due to their reliable and growing payouts. Johnson & Johnson boasts a 64-year streak of dividend increases supported by accele...
PepsiCo announced that Joaquin Duato, Chairman and CEO of Johnson & Johnson, will join its Board of Directors as an independent member effective December 1, 2026. Duato will serve on the Audit Committee, bringing over three decades of leadership expe...
